VANCOUVER, July 23 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today filed a preliminary short form base shelf prospectus with the securities commissions of British Columbia and Ontario and a corresponding shelf registration statement on Form S-3 with the United States Securities and Exchange Commission (collectively, the "Offering Documents"). The Offering Documents, when made final and / or declared effective, will allow Angiotech to make offerings of Common shares, Class I Preference shares, debt securities, warrants or units for initial aggregate proceeds of up to US$250 million during the next 25 months to potential purchasers in British Columbia, Ontario and the United States. Angiotech intends to use the proceeds from any such offering for general corporate purposes, including funding research and development programs, capital expenditures, working capital and/or repayment or refinancing of the Company's outstanding indebtedness, except as otherwise indicated in the applicable prospectus supplement related to any such offering.
A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Forward Looking Statements --------------------------
Statements contained in this press release that are not based on historical
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved